Across TCGA pan-cancer cohorts, SVIP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SVIP data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher SVIP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SVIP expression acts as an unfavorable survival marker.

PRAD are the cancer types where SVIP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: SVIP tumor-vs-normal RNA expression · all SVIP data types